CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of cardiac and renal dysfunction, also known as cardiorenal disease, today announced the pricing of its initial public offering of 1,925,000 units at $6.50 per unit (before underwriting discounts and commissions). Each unit consists of two shares of CorMedix common stock and a warrant to purchase one share of common stock at a price of $3.4375. All of the units are being offered by CorMedix. The units are expected to begin trading today on the NYSE Amex under the symbol “CRMD.U”. In addition, CorMedix has granted the underwriters a 45-day option to purchase up to an additional 288,750 units to cover over-allotments, if any. Maxim Group LLC is the sole book-running manager for the offering.
The offering of these securities will be made only by means of a prospectus, copies of which may be obtained from Maxim Group LLC, 405 Lexington Ave, New York, NY 10174, or by telephone at 212-895-3685.
Natural obesity fighters: How coffee, tea, and cocoa combat weight gain